Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and families who screen positive, and 3) evaluate the Early Check program. The Early Check screening will lead to earlier identification of newborns with rare health conditions in addition to providing important data on the implementation of this model program. Early diagnosis may result in health and development benefits for the newborns. Infants who have newborn screening in North Carolina will be eligible to participate, equating to over 120,000 eligible infants a year. Over 95% of participants are expected to screen negative. Newborns who screen positive and their parents are invited to additional research activities and services. Parents can enroll eligible newborns on the Early Check electronic Research Portal. Screening tests are conducted on residual blood from existing newborn screening dried blood spots. Confirmatory testing is provided free-of-charge for infants who screen positive, and carrier testing is provided to mothers of infants with fragile X. Affected newborns have a physical and developmental evaluation. Their parents have genetic counseling and are invited to participate in surveys and interviews. Ongoing evaluation of the program includes additional parent interviews.

Start Date15 Oct 2018

Sponsor / Collaborator

Research Triangle Institute

[+15]

100 Clinical Results associated with Asuragen, Inc.

0 Patents (Medical) associated with Asuragen, Inc.

Literatures (Medical) associated with Asuragen, Inc.

01 May 2024·C97. TOBACCO, E-CIGARETTES, AND AIR POLLUTION: MAJOR ENVIRONMENTAL THREATS TO LUNG HEALTH

In Utero Exposure to Electronic Nicotine Delivery System Aerosol Alters Mouse Lung Development Via Impaired IL-10 Immunoregulation

Author: Yilmaz, S. ; Penn, A.L. ; Perveen, Z. ; Xiao, R. ; Noel, A.

20 May 2021·Journal of Clinical Oncology

Comprehensive genomic and transcriptomic profiling of pediatric malignancies using the Tempus xT Next-Generation Sequencing Assay to identify clinically meaningful alterations.

Author: Schwarzbach, Anna Ewa ; Kwiatkowska-Piwowarczyk, Aneta ; Thomas, Stefanie Marie ; Toll, Stephanie ; Kaneva, Kristiyana ; Schaeffer, Jeff

e22002 Background: Our understanding of the genomic makeup of childhood cancers has accelerated over the past decade largely due to next-generation sequencing (NGS) utilized to identify genetic drivers, aid diagnostics and risk stratification, and detect therapeutic targets. Here, we present the genomic and transcriptomic landscape of pediatric malignancies tested with a broad NGS panel at a large commercial CLIA/CAP laboratory, Tempus Labs. Methods: We used the Tempus LENS platform to analyze DNA- and RNA-seq data from a cohort of 150 de-identified records of patients with pediatric cancer aged 0 to 18 years who underwent NGS with the Tempus xT platform. Results: The cohort included 139 solid tumors, 46 of which were central nervous system (CNS) tumors, and 11 hematologic malignancies. A total of 115 samples (77%) had at least one clinically meaningful pathogenic somatic variant detected, with TP53 variants being the most common (n=26; 17.3%). Gene fusions, most commonly EWSR1-FLI1 and KIAA1549-BRAF, were observed in 31 cases (20.7%). Matched tumor/normal testing revealed at least one incidental pathogenic germline variant in six patient records, with two cases harboring two distinct variants. Four cases had tumor mutational burdens (TMBs) greater than 10 mutations/megabase, including two that also exhibited high microsatellite instability (MSI). Conclusions: The Tempus xT tumor/normal-matched platform detects clinically meaningful genomic alterations in pediatric cancers important for diagnosis, prognosis, therapeutic target identification, and incidental germline findings. We continue to accumulate and structure data to meet the need for a large, accessible pediatric cancer clinical and molecular dataset. [Table: see text]

15 Aug 2020·Cancer Research

Abstract 6296: Multiplexed protein and RNA quantification on a single instrument harmonizes multi-omic analyses of biomarkers for immunotherapies and targeted therapies in non-small cell lung cancer

Author: Khan, Yasef ; Gokul, Shobha ; Manzano, Lawrence ; Latham, Gary J. ; Leong, Louis ; Ramirez, Francisco ; Heger, Chris

AbstractIntroduction: Integration of multiple classes of biomarkers, including proteins, DNA and RNA, offers insights into the complexities of spatial, temporal, and functional biology beyond those possible with any one class. The distinct properties and detection modalities of protein and nucleic acid, however, require different technologies and platforms, thereby limiting their utility in a single-assay format. We developed a multiplexed multi-omic workflow using an established protein analysis system (Simple Western, ProteinSimple) to assess both proteins and nucleic acids. We demonstrate that this system and workflow can quantify at least six well-established proteins and RNA biomarkers for immunotherapies and targeted therapies for non-small cell lung cancer (NSCLC).Methods: The multi-omic workflow required only three steps. First, protein and RNA were extracted from cell lines or clinical FFPE tumor biopsies. Second, hapten-labeled amplicons were prepared using single-tube multiplex RT-PCR. Finally, both amplicons and proteins were separated on a Simple Western instrument, detected by immunoassay, and analyzed. RNA quantification via RT-PCR was normalized to either total RNA or a stable reference gene, and compared with multiple orthogonal assays, including nucleic acid fragment capillary electrophoresis (CE) system and RT-qPCR.Results: PCR or RT-PCR amplicons from EML4-ALK RNA fusions, PD-L1 and PD-L2 transcripts, and a reference mRNA were designed with varying amplicon lengths for CE separation optimization. RNA-based products were quantified with a linear dynamic range of ~2 logs using Simple Western. The relative expression of PD-L1 RNA in four cancer cells was consistent using this approach compared to two other CE systems and qPCR. Further, the results matched published data (rank order A549 < PC9 < H460 < H441). PD-L1 protein levels assessed on the same system were also consistent with literature data. EML4-ALK expression agreed with known results for both ALK-positive and negative cell lines. All results were then recapitulated in a single-workflow, 6-plex RNA and protein assay. Finally, multiplexed protein and RNA expression of NSCLC FFPE tumor biopsies was measured simultaneously and compared.Conclusions: We demonstrate that a technology (Simple Western) originally developed for protein analysis is capable of analyzing nucleic acids. We also show the potential utility of this system to quantify protein and RNA biomarkers relevant to immune checkpoint blockade and targeted therapies, as shown for NSCLC. This novel approach can combine protein, DNA and RNA quantification in one harmonized, multiplexed workflow with reduced sample requirements, and decreased inter-assay variability, with a more streamlined and less error-prone workflow.Citation Format: Yasef Khan, Francisco Ramirez, Shobha Gokul, Lawrence Manzano, Louis Leong, Gary J. Latham, Chris Heger. Multiplexed protein and RNA quantification on a single instrument harmonizes multi-omic analyses of biomarkers for immunotherapies and targeted therapies in non-small cell lung cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6296.

News (Medical) associated with Asuragen, Inc.

11 Jul 2024

·www.businesswire.com

mRNA Platform Global Strategic Research Report 2024: Increasing Prevalence of Infectious & Chronic Conditions to Unleash Gains & Help mRNA Vaccines Market Gallop Ahead - Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "mRNA Platform - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for mRNA Platform was valued at an estimated US$149.9 Billion in 2023 and is projected to reach US$120.2 Billion by 2030, growing at a CAGR of -3.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growth in the mRNA platform market is driven by several factors, including the increasing incidence of infectious diseases, advancements in mRNA technology, and significant investments in biotechnology research. The ongoing threat of pandemics and the need for swift and effective responses have highlighted the importance of mRNA vaccines, spurring demand and investment in this technology. Technological advancements, such as improved delivery systems and more efficient manufacturing processes, have enhanced the scalability and efficacy of mRNA-based products. Furthermore, substantial investments from both public and private sectors are accelerating research and development activities, leading to new therapeutic applications and expanding the market potential. Regulatory support and expedited approval processes for mRNA vaccines and therapies have also contributed to the rapid growth of this market. These factors collectively underscore the transformative impact of the mRNA platform in modern medicine and its potential to address a wide range of health challenges. Key Insights: Market Growth: Understand the significant growth trajectory of the COVID-19 Vaccine segment, which is expected to reach US$96.5 Billion by 2030 with a CAGR of a -6.1%. The Cancer Vaccine segment is also set to grow at 104.7% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $67.5 Billion in 2023, and China, forecasted to grow at an impressive -0.8% CAGR to reach $13.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Why You Should Buy This Report: Detailed Market Analysis: Access a thorough analysis of the Global mRNA Platform Market, covering all major geographic regions and market segments. Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies. Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global mRNA Platform Market. Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions. Key Questions Answered: How is the Global mRNA Platform Market expected to evolve by 2030? What are the main drivers and restraints affecting the market? Which market segments will grow the most over the forecast period? How will market shares for different regions and segments change by 2030? Who are the leading players in the market, and what are their prospects? Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of major players such as AstraZeneca PLC, Asuragen, Inc., Catalent Pharma Solutions, and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Topics Covered: MARKET OVERVIEW mRNA Platform - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) mRNA - A CONCEPTUAL UNDERSTANDING mRNA: A New Approach to Medicine Long Wait & Scientific Breakthroughs mRNA Vaccines - An Introduction With Unparalleled Turnaround Time, mRNA Platform Adds Revolutionary Dimension to Vaccine Development mRNA: Making Cells Act as Vaccine Factory mRNA Vaccines: Advantages mRNA Vaccines: Cons mRNA Vaccine Approvals A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine Traditional Vs. mRNA Vaccines: Key Differences Traditional Vs. mRNA Vaccines: The Development Process How mRNA Vaccine Works & Earlier Testing Efforts mRNA Vaccines: Safety Quotient Other Notable Efforts Centered on mRNA Technology Overcoming Challenges As Serious Candidate, mRNA Technology Warrants Attention from Scientific Community GLOBAL MARKET OVERVIEW Global mRNA Vaccines Market on a Dynamic Growth Track mRNA Vaccines Could Vanquish Cancer and Other Diseases, Cancer Segment to Make Major Contribution to Global mRNA Vaccines Market The US Holds Leading Position, while Asia-Pacific Exhibits Lucrative Growth in mRNA Vaccines Market Faster, Effective and Cheaper: Adaptability of mRNA Vaccine Unleashes Potential Utility for Developing Nations RECENT MARKET ACTIVITY IN THE COVID-19 VACCINE SPACE Pfizer and BioNTech's COVID-19 Vaccine Receives World's First Authorization UK Clinches the First Position in the World to Approve Pfizer's Vaccine After UK, US Gives Nod to Pfizer's Vaccine EU Approves Pfizer's Vaccine BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU Novartis Inks Agreement with Pfizer-BioNtech to Support COVID-19 Vaccine Production FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021) Moderna's mRNA Vaccine Bags Approval from US FDA Moderna Kick-Starts Inoculation in the US FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021) Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021) Recent Market Activity COMPETITIVE SCENARIO BioNTech - A Pioneer in mRNA-based Vaccines and Therapies List of BioNTech's mRNA Candidates in Clinical Trials for Cancer Moderna's Ambitious Stride into Vaccine Development: From a Novice to Know All Moderna's mRNA Prophylactic Vaccines mRNA Cancer Vaccines mRNA Intratumoral Immuno-Oncology mRNA Systemic Secreted & Cell Surface Therapeutics mRNA Systemic Intracellular Therapeutics Sanofi Commences Clinical Trials of mRNA vaccine for COVID-19 mRNA as Promising Vaccine Technology Entices Startups to Join the Bandwagon Noteworthy Startups Exploiting mRNA Technology Providence Therapeutics pHion Therapeutics eTheRNA immunotherapies & 20Med Therapeutics MARKET TRENDS & DRIVERS Increasing Prevalence of Infectious & Chronic Conditions to Unleash Gains & Help mRNA Vaccines Market Gallop Ahead mRNA Vaccines Development for Other Infectious Diseases and Therapeutic Areas Gains Momentum Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market Increasing Healthcare Expenditure to Foster Market Growth Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth Regulatory Landscape for mRNA Vaccines Regulatory Pathway Dealing with mRNA Vaccines mRNA Vaccine Patent Scenario The Best Route of Administration for mRNA Vaccines mRNA CANCER VACCINES Introduction Cancer Vaccines Vs. Immunotherapies Clinical Trials of mRNA Encoding Immunostimulants mRNA Vaccines Vs. DNA Vaccines Clinical Trials of mRNA Encoding TAAs mRNA Vaccines Vs. Other Vaccines Clinical Trials of mRNA Vaccines Encoding Neoantigens (Neo-Ag) mRNA Benefits Profile mRNA Vaccines for COVID-19 Pave the Way Challenges Personalized mRNA Vaccine Clinical Overview of mRNA Cancer Vaccines mRNA encoding Immunostimulants mRNA vaccine encoding tumor-associated antigens mRNA vaccine encoding Neoantigen, personalized vaccine mRNA Influenza Vaccines Perpetual Evolution of Influenza Viruses Makes mRNA a Fascinating Vaccine Platform Vaccines Built on mRNA Clinical Trials for mRNA Vaccines mRNA Vaccine as Game Changer for Flu Viruses Eluding Conventional Vaccine Efforts mRNA: A Next-Generation Vaccination Approach Moderna Moves Ahead to Brew Novel mRNA Vaccines for Influenza & Other Viruses COVID-19 Vaccine Technology to Foster Development of Effective Flu Shots mRNA Vaccines Vs. Other Flu Shots mRNA Technology, H/N Spike Proteins & Clinical Trials mRNA Technology: A Suitable Candidate for Universal & Effective Influenza Vaccines Benefits & Limitations of mRNA Vaccines over Traditional Options FOCUS ON SELECT PLAYERS (Total 96 Featured) AstraZeneca PLC Asuragen, Inc. Catalent Pharma Solutions Altogen Labs Arcturus Therapeutics, Inc. BioNTech AG CRISPR Therapeutics Aldevron AKESOgen, Inc. baseclick GmbH chimeron bio Acuitas Therapeutics Accent Therapeutics Accanis Biotech F&E GmbH & Co KG Avectas For more information about this report visit https://www.researchandmarkets.com/r/34yhs4 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

VaccineDrug ApprovalImmunotherapymRNAClinical Study

22 Mar 2024

·www.prnewswire.com

BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA

The QuantideX® qPCR BCR-ABL IS Kit is now compliant with the latest diagnostic regulations in Europe MINNEAPOLIS, March 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne's Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX® qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive (IVDD), which has now been replaced by the IVDR. The QuantideX qPCR BCR-ABL IS Kit gives labs a robust and reliable tool for monitoring chronic myeloid leukemia (CML) patients. The highly sensitive qPCR-based in vitro diagnostic test quantifies BCR-ABL1 and ABL1 transcripts in blood samples from patients with CML to determine their response to tyrosine kinase inhibitor (TKI) therapy. CML patients must undergo regular monitoring to ensure that they continue to receive the most appropriate treatment for their cancer. The QuantideX kit allows for direct reporting on the International Scale and further streamlines the workflow with easy-to-use analysis software. Clinical lab scientists can run up to 49 samples per plate for a scalable solution. "Bio-Techne is dedicated to quality and compliance, and we applaud this new IVDR for strengthening the safety and performance requirements for diagnostic products," said Matt McManus, President of Bio-Techne's Diagnostics & Genomics Segment. "We are proud to achieve this new certification and will continue to provide the molecular diagnostic and liquid biopsy solutions that deliver world-class performance, scalability, and reliable results for the laboratory scientists, physicians, and patients who count on us." About Bio-Techne: Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate Development [email protected] 612-656-4416 SOURCE Bio-Techne Corporation

Diagnostic Reagents

12 Feb 2024

·www.businesswire.com

Next-Generation Sequencing Emerging Clinical Applications and Global Markets, with Profiles of Leading Players Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies and BGI Genomics - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering. Since NGS platforms can sequence an entire genomic region or even an entire genome, a single test can examine hundreds or thousands of clinically important genetic variations. This means that one test can replace multiple conventional single-gene tests, providing an advantage in price and in the amount of precious sample needed for the test itself. NGS is often more accurate and reliable than existing diagnostics. This can result in better clinical outcomes. For example, NGS can increase the pregnancy success rates in in vitro fertilization applications. Also, in rare genetic diseases, NGS can increase the success rates for determining a molecular diagnosis. The NGS platform enables companies to expand the menu of disorders/diseases over time after initial launch of a test. This strategy has been employed in reproductive health applications, for example, launching a test to initially screen for aneuploidies, and then later expanding the test to include screening for additional genetic variants. These features of NGS platforms provide a solid basis for the use of this technology in the clinic. The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies. The markets for NGS-based diagnostics are given for the years 2020, 2021, 2022, 2023 and 2028. This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the significant research initiatives that impact clinical NGS applications. Liquid biopsy formats are discussed. The main market driving forces are also discussed. The report examines the markets by test complexity, clinical indication and test purpose. Test complexity refers to the plex level (i.e., the number of genetic markers that can be analyzed within a sample) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics, etc.) will be in demand in the future. The report provides market data and forecasts for NGS diagnostics by specific applications, including those for oncology, cardiovascular diseases, clinical microbiology/infectious diseases, Mendelian disorders, metabolic/immune disorders, neurological disorders, reproductive health, and transplant medicine. Industry sectors analyzed include DNA sequencing instruments; long-read sequencing; sequencing informatics; target enrichment; CTC capture and detection; liquid biopsy; cancer screening/early detection; direct-to-consumer testing; and noninvasive prenatal testing. More than 100 companies in the clinical NGS industry are profiled in this report. The Report Includes 41 data tables and 237 additional tables An overview of the global market for emerging clinical applications of next-generation sequencing Analysis of global market trends, featuring historical revenue data for 2020 to 2022, estimates for 2023, as well as forecasts for 2028, including projections of compound annual growth rates (CAGRs) through 2028 Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by disease indication, test complexity, test purpose, application and geographic region Discussion of market opportunities for clinical NGS products, clinical applications, industry structure, regulatory scenarios and use of NGS-based diagnostics and technologies Coverage of genome mapping programs, technological advances and innovations in NGS platforms, and the Ion Torrent Genexus System from Thermo Fisher Scientific and the Magnis NGS Prep System from Agilent Technologies Inc Description of NGS-oriented tests such as non-invasive prenatal testing (NIPT) and pre-implantation genetic testing (PGT), and a discussion of their advantages Market share analysis of the key companies and a look at their proprietary technologies, strategic alliances and other key market strategies, plus a patent analysis Profiles of the leading players, including Illumina Inc., Thermo Fisher Scientific Inc., QIAGEN, Agilent Technologies Inc., and BGI Genomics Key Attributes: Report Attribute Details No. of Pages 492 Forecast Period 2023 - 2028 Estimated Market Value (USD) in 2023 $21.9 Billion Forecasted Market Value (USD) by 2028 $52.9 Billion Compound Annual Growth Rate 19.3% Regions Covered Global Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Overview Liquid and Tissue Biopsy Clinical NGS Market Growth Drivers of Clinical NGS Key Trends Industry Chapter 4 Technology Background Importance of DNA Genetic Variation and Analysis Genetic Analysis Technologies Sequencing in Clinical Applications Sequencing Technologies History of DNA Sequencing Sanger Sequencing Technology NGS Platforms Short-Read Platforms Long-Read Platforms Informatics Technologies Base Calling Mapping to a Reference Sequence Variant Analysis Artificial Intelligence Technologies Clinical Sequencing Technology Challenges Chapter 5 Clinical NGS Initiatives and Emerging Technologies R&D Initiatives and Programs 1+ Million Genomes Access to Treatment and Testing (ACTT) Access to Comprehensive Genomic Profiling Coalition (ACGP) Africa Pathogen Genomics Initiative Blood Profiling Atlas Cancer-ID Cancer Moon Shots Program China Precision Medicine Initiative ClinGen CTC Trap Consortium diaRNAgnosis Project Early Cancer Detection Consortium EpiFemCare France Genomic Medicine Plan Friends of Cancer Research Project Genomic Medicine Sweden HCA-Organoid Human Cell Atlas Human Immunomics Initiative Immunomonitor Consortium Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program Intervene Liquid Biopsies and Imaging for Improved Cancer Care Liquid Biopsy-Based Malignant Tumor Early Screening Technology Research and Development Project Liver Cancer Early Screening Comprehensive Prevention and Control Project Lung Cancer Genomic Screening Project for Individualized Medicine in Asia Million Veteran Program Medical Genome Initiative MedSeq Precision Medicine Initiative Prompt QuIP Project SPHERES Target ALS Diagnosis Initiative TopMed Treehouse Childhood Cancer Initiative Very Rare Cancer Consortium Worldwide Innovative Networking (WIN) Consortium Single-Cell Research Cambridge Single-Cell Analysis Core Facility Harvard Medical School Single-Cell Core Mayo Medical Genome Facility National Center for Single-Cell Biology Next-Generation Single-Cell Analysis Program Single-Cell Analysis Core UC San Francisco Single-Cell Analysis Center The Wistar Institute of Anatomy and Biology Population Sequencing Projects Chapter 6 Clinical NGS Applications Chapter 7 Clinical NGS Industry Chapter 8 ESG Development Chapter 9 Acquisitions and Strategic Alliances Chapter 10 Clinical NGS Markets Chapter 11 Patent Review Chapter 12 Company Profiles Agilent Technologies Inc. Bgi Genomics Co. Ltd Illumina Inc. Qiagen Thermo Fisher Scientific Inc. Accuragen Holdings Adaptive Biotechnologies Alcen Ambry Genetics Amoy Diagnostics Co. Ltd. Angle Plc Apostle Sciences Arcedi Biotech Aps Armonica Technologies Inc. Arup Laboratories Asuragen Inc. Baylor Genetics Becton, Dickinson And Co. Berry Genomics Beijing Biocaptiva Ltd. Biocept Inc. Biodesix Biofluidica Biolidics Ltd Biological Dynamics Biomodal Bionano Genomics Bio-Rad Laboratories Inc. Bio-Techne C2I Genomics Capio Biosciences Caredx Inc. Caris Life Science Cegat Gmbh Cell Microsystems Centrillion Genomics Technologies Claret Bioscience Clear Note Health Clinical Genomics Technologies Cyclomics Cygnus Biosciences Co. Ltd. Danaher Dante Labs Datar Cancer Genetics Ltd. Delfi Diagnostics Diacarta Diagnologix Llc Diagnomics Inc. Diamir Bio Dnalytics Dnanexus Inc. Earlydiagnostics Epic Sciences Epigenomics Ag Eurofins Genomics Everly Health Inc. Exact Sciences Corp. Exopert Exosomics Inc. Ezlife Bio Fabric Genomics Inc. F. Hoffmann-La Roche Ltd Fluxion Biosciences Inc. Freenome Holdings Inc. Fulgent Genetics Full Genomes Corp. Gene By Gene Ltd. Genedx Llc Geneseq Biosciences Genomoncology Llc Genosaber Grail Inc. Guardant Health Helio Genomics Helix Inc. Htg Molecular Diagnostics Inc. Imagia Canexia Health Incelldx Inc. Inex Innovate Private Ltd Inoviq Interpace Biosciences Inc. Invitae Corp. Invivoscribe Inc. Jabrehoo Med Tech Co. Ltd. Jbs Science Jumpcode Genomics Koninklijke Philips Labgenomics Lucence Health Macrogen Mapmygenome Mdxhealth Inc. Medgenome Medicover Genetics Merck Kgaa Micareo Rare Cell Diagnostics Micronoma Inc. Mir Scientific Mutantdx Myriad Genetics Inc. Nanostring Technologies Inc. Natera Inc. Nebula Genomics Neogenomics Laboratories New England Biolabs New Horizon Health Ltd. Novigenix Novogene Co. Ltd. Nrichdx Inc. Nuprobe Inc. Nx Prenatal Inc. Oncimmune Holdings Plc Oncocyte Corp. Oncodna Opko Health Orchid Oxford Nanopore Technologies Ltd. Pangaea Oncology Personal Genome Diagnostics Inc. Personalis Inc. Phase Scientific Pieriandx Predicine Prenetics Group Qcdx Llc Quantapore Quantgene Inc. Quantumdx Quest Diagnostics Rarecells Inc. Ravgen Real Time Genomics Resolution Bioscience Inc. Saga Diagnostics Sano Genetics Screencell Seekin Inc. Sequencing.Com Seven Bridges Genomics Inc. Single Technologies Smartcatch Strand Strata Oncology Syapse Inc. Sysmex Inostics Takara Bio Inc. Telexos Gmbh Twinstrand Biosciences Inc. Twist Bioscience Unchained Labs Universal Dx Vela Diagnostics Veracyte Volitionrx Vortex Biosciences Yourgene Health Yikon Genomics For more information about this report visit https://www.researchandmarkets.com/r/tklgxp About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

100 Deals associated with Asuragen, Inc.

100 Translational Medicine associated with Asuragen, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 18 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Asuragen, Inc.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 18 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing